Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults. 2005

Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
Division of Cardiac Surgery and Anesthesiology, University of Verona, OCM Borgo Trento, Piazzale Stefani 1, 37126, Verona, Italy. fsant@yahoo.com

BACKGROUND Inhaled nitric oxide (iNO) is proposed in the management of pulmonary hypertension (PH) in patients undergoing cardiac surgery. Secondary PH related to a long-standing heart valve disease however may be refractory to iNO. Aim of this prospective study was to determine whether the combination of iNO plus dipyridamole (DP), a cyclic guanosine monophosphate-specific phosphodiesterase inhibitor (PDE5), may enhance and/or prolong the response to iNO in adult patients with secondary valve-related PH undergoing cardiac surgery, and attenuate rebound events related to its discontinuation. METHODS Responses in 27 patients, 11 male, mean age 72+/-11 years, with PH due to mitral and/or aortic valve disease, were studied in the Intensive Care Unit after cardiac surgery, during sedation and stable hemodynamic conditions. The effect of isolated iNO administration (40 ppm), iNO combined with DP (0.2 mg/kg i.v.), and DP alone (1 mg/kg/24 h) on pulmonary vascular resistance, mean pulmonary artery pressure, cardiac index, mixed venous O2Sat%, and mean arterial pressure were determined. RESULTS All patients showed at least a 10% decrease in pulmonary vascular resistance vs. baseline after administration of iNO [responders]. Inhaled NO and the combination of iNO/DP produced a reduction of pulmonary vascular resistance and mean pulmonary artery pressure (p<0.05). Cardiac index improved with a significant difference between iNO and the association iNO/DP versus baseline (p<0.05). This significant hemodynamic improvement versus baseline was maintained during isolated DP administration (p<0.05), but not during isolated iNO discontinuation. Mixed venous oxygen saturation showed an overall improvement of 17% (p<0.05). CONCLUSIONS Inhaled NO and DP infusion might represent a valuable association in the management of PH secondary to a heart valve disease in patients undergoing cardiac surgery. Their beneficial hemodynamic effects might be particularly valuable in the management of patients with associated right ventricular dysfunction.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008943 Mitral Valve The valve between the left atrium and left ventricle of the heart. Bicuspid Valve,Bicuspid Valves,Mitral Valves,Valve, Bicuspid,Valve, Mitral,Valves, Bicuspid,Valves, Mitral
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011652 Pulmonary Circulation The circulation of the BLOOD through the LUNGS. Pulmonary Blood Flow,Respiratory Circulation,Circulation, Pulmonary,Circulation, Respiratory,Blood Flow, Pulmonary,Flow, Pulmonary Blood,Pulmonary Blood Flows
D011669 Pulmonary Wedge Pressure The blood pressure as recorded after wedging a CATHETER in a small PULMONARY ARTERY; believed to reflect the PRESSURE in the pulmonary CAPILLARIES. Pulmonary Artery Wedge Pressure,Pulmonary Capillary Wedge Pressure,Pulmonary Venous Wedge Pressure,Wedge Pressure,Pressure, Pulmonary Wedge,Pressures, Pulmonary Wedge,Pulmonary Wedge Pressures,Wedge Pressure, Pulmonary,Wedge Pressures, Pulmonary,Pressure, Wedge,Pressures, Wedge,Wedge Pressures

Related Publications

Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
July 1998, Chest,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
November 1998, American journal of respiratory and critical care medicine,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
October 1996, Intensive care medicine,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
May 1995, Zhonghua yi xue za zhi,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
April 1998, The Journal of thoracic and cardiovascular surgery,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
January 2005, Respiration; international review of thoracic diseases,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
October 1994, Journal of the American College of Cardiology,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
January 2001, The American journal of cardiology,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
November 2002, Pediatric research,
Francesco Santini, and Gianluca Casali, and Gianluigi Franchi, and Stefano Auriemma, and Mario Lusini, and Luca Barozzi, and Alessandro Favaro, and Antonio Messina, and Alessandro Mazzucco
January 2013, Pulmonary circulation,
Copied contents to your clipboard!